Bupropion Mediated Effects on Depression, Attention Deficit Hyperactivity Disorder, and Smoking Cessation.

Bupropion had been in use since the late 1980s as an unconventional treatment for depression. Unlike other antidepressants, bupropion has no serotonergic activity and inhibits the reuptake of norepinephrine and dopamine. The drug has been used to treat depression, Attention Deficit Hyperactivity Disorder (ADHD), and smoking cessation. This investigation reviews the pharmacokinetic and pharmacodynamic effects of bupropion and its mechanisms of action and interactions with other drugs. We evaluated the efficacy of major on and off-label uses of bupropion, focusing on the indications, benefits, and adverse effects. Our review demonstrates that bupropion is superior to placebo and non-inferior to SSRIs such as escitalopram in treating major depressive disorder. More research is needed to determine positive patient-centered outcomes such as increases in quality of life. In the case of ADHD, the evidence for efficacy is mixed with poorly conducted randomized clinical trials, small sample sizes, and a lack of long-term assessments. The same is true in the case of bipolar disorder in which there is still limited and controversial data available on bupropion's safety and efficacy. In the case of smoking cessation, bupropion is found to be an effective anti-smoking drug with synergistic benefits when used as a combination therapy. We conclude that bupropion has the potential to provide benefit for a subset of patients who do not tolerate other typical antidepressants or anti-smoking therapies or for those whose treatment goals align with bupropion's unique side effect profile, such as smokers who wish to quit and lose weight. Additional research is needed to determine the drug's full clinical potential, particularly in the areas of adolescent depression and combination therapy with varenicline or dextromethorphan. Clinicians should use this review to understand the varied uses of the drug and identify the situations and patient populations in which bupropion can lend its greatest benefit.

[1]  H. Schiöth,et al.  Treatment of ADHD: Drugs, psychological therapies, devices, complementary and alternative methods as well as the trends in clinical trials , 2022, Frontiers in Pharmacology.

[2]  T. Ikuta,et al.  Antidepressants for the treatment of adults with major depressive disorder in the maintenance phase: a systematic review and network meta-analysis , 2022, Molecular Psychiatry.

[3]  C. S. Hendershot,et al.  Effects of varenicline and bupropion on laboratory smoking outcomes: Meta‐analysis of randomized, placebo‐controlled human laboratory studies , 2022, Addiction biology.

[4]  M. Fava,et al.  Efficacy and Safety of AXS-05 (Dextromethorphan-Bupropion) in Patients With Major Depressive Disorder: A Phase 3 Randomized Clinical Trial (GEMINI). , 2022, The Journal of clinical psychiatry.

[5]  D. Iosifescu,et al.  Effect of AXS-05 (Dextromethorphan-Bupropion) in Major Depressive Disorder: A Randomized Double-Blind Controlled Trial. , 2022, The American journal of psychiatry.

[6]  Jennifer A. Minnix,et al.  The effects of varenicline, bupropion, nicotine patch, and placebo on smoking cessation among smokers with major depression: A randomized clinical trial , 2022, Depression and anxiety.

[7]  Kehu Yang,et al.  The effect of Varenicline and Bupropion on smoking cessation: A network meta-analysis of 20 randomized controlled trials. , 2022, Addictive behaviors.

[8]  T. Bschor,et al.  Combining Antidepressants vs Antidepressant Monotherapy for Treatment of Patients With Acute Depression: A Systematic Review and Meta-analysis. , 2022, JAMA psychiatry.

[9]  N. Rigotti,et al.  Treatment of Tobacco Smoking: A Review. , 2022, JAMA.

[10]  Liang-Jen Wang,et al.  The comparative effectiveness of antidepressants for youths with major depressive disorder: a nationwide population-based study in Taiwan , 2022, Therapeutic advances in chronic disease.

[11]  Liang-Jen Wang,et al.  Comparative Effectiveness of Antidepressants on Geriatric Depression: Real-world Evidence from a Population-based Study. , 2021, Journal of affective disorders.

[12]  B. Hutton,et al.  Time to Update Evidence-Based Guideline Recommendations About Concurrent Tamoxifen and Antidepressant Use? A Systematic Review. , 2021, Clinical breast cancer.

[13]  R. Goldman,et al.  Bupropion for smoking cessation in adolescents , 2021, Canadian Family Physician Médecin de famille canadien.

[14]  D. McCabe,et al.  The Timing of Clinical Effects of Bupropion Misuse Via Insufflation Reported to a Regional Poison Center. , 2021, The Journal of emergency medicine.

[15]  M. Amore,et al.  Antidepressant Drugs Effects on Blood Pressure , 2021, Frontiers in Cardiovascular Medicine.

[16]  C. Masimirembwa,et al.  CYP2B6 Functional Variability in Drug Metabolism and Exposure Across Populations—Implication for Drug Safety, Dosing, and Individualized Therapy , 2021, Frontiers in Genetics.

[17]  K. Leander,et al.  CYP2D6-inhibiting drugs and risk of fall injuries after newly initiated antidepressant and antipsychotic therapy in a Swedish, register-based case-crossover study , 2021, Scientific Reports.

[18]  Jillian T Henderson,et al.  Interventions for Tobacco Cessation in Adults, Including Pregnant Persons: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. , 2021, JAMA.

[19]  H. Kranzler,et al.  Placebo-Controlled Trial of Bupropion for Smoking Cessation in Pregnant Women. , 2021, American journal of obstetrics & gynecology MFM.

[20]  J. Son,et al.  Comprehensive Review of Current and Upcoming Anti-Obesity Drugs , 2020, Diabetes & metabolism journal.

[21]  M. Pirmohamed,et al.  A Review of the Important Role of CYP2D6 in Pharmacogenomics , 2020, Genes.

[22]  R. Sarzani,et al.  Pharmacological Approach to Smoking Cessation: An Updated Review for Daily Clinical Practice , 2020, High Blood Pressure & Cardiovascular Prevention.

[23]  Jaekyu Shin,et al.  Combining Antidepressants with β‐Blockers: Evidence of a Clinically Significant CYP2D6 Drug Interaction , 2020, Pharmacotherapy.

[24]  M. Picciotto,et al.  Mechanisms of Nicotine Addiction. , 2020, Cold Spring Harbor perspectives in medicine.

[25]  M. Abesamis,et al.  Serotonin toxicity from isolated bupropion overdoses , 2020, Clinical toxicology.

[26]  R. Pandey,et al.  Nicotine Addiction: Neurobiology and Mechanism , 2020, Journal of pharmacopuncture.

[27]  Bupropion , 2020, Reactions Weekly.

[28]  Xiufeng Xu,et al.  Efficacy and safety of bupropion hydrochloride extended-release versus escitalopram oxalate in Chinese patients with major depressive disorder: Results from a randomized, double-blind, non-inferiority trial. , 2019, Journal of affective disorders.

[29]  Shuyue Xia,et al.  Combination therapy of varenicline and bupropion in smoking cessation: A meta-analysis of the randomized controlled trials. , 2019, Comprehensive psychiatry.

[30]  R. Dinis-Oliveira,et al.  Pharmacokinetic and pharmacodynamic of bupropion: integrative overview of relevant clinical and forensic aspects , 2019, Drug metabolism reviews.

[31]  F. Shokraneh,et al.  Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis , 2018, The lancet. Psychiatry.

[32]  Y. Kanbay,et al.  Treatment adherence and short-term outcomes of smoking cessation outpatient clinic patients , 2018, Tobacco induced diseases.

[33]  R. Goodwin,et al.  Socioeconomic Disparities in Smoking Among U.S. Adults With Depression, 2005-2014. , 2018, American journal of preventive medicine.

[34]  I. Gräff,et al.  Adverse Drug Reactions (ADR) and Emergencies. , 2018, Deutsches Arzteblatt international.

[35]  G. Russo,et al.  Adverse Drug Reactions in Hospitalized Patients: Results of the FORWARD (Facilitation of Reporting in Hospital Ward) Study , 2018, Front. Pharmacol..

[36]  Z. Xi,et al.  Discovery and development of varenicline for smoking cessation , 2018, Expert opinion on drug discovery.

[37]  T. Patel,et al.  Mortality among patients due to adverse drug reactions that lead to hospitalization: a meta-analysis , 2018, European Journal of Clinical Pharmacology.

[38]  Jie Gao,et al.  An Evaluation on the Efficacy and Safety of Treatments for Attention Deficit Hyperactivity Disorder in Children and Adolescents: a Comparison of Multiple Treatments , 2016, Molecular Neurobiology.

[39]  W. Van den Noortgate,et al.  Bupropion for attention deficit hyperactivity disorder (ADHD) in adults. , 2017, The Cochrane database of systematic reviews.

[40]  D. Moher,et al.  The pharmacological and non-pharmacological treatment of attention deficit hyperactivity disorder in children and adolescents: A systematic review with network meta-analyses of randomised trials , 2017, PloS one.

[41]  G. Harrington,et al.  Pharmacokinetics and Pharmacogenomics of Bupropion in Three Different Formulations with Different Release Kinetics in Healthy Human Volunteers , 2017, The AAPS Journal.

[42]  Q. Ng A Systematic Review of the Use of Bupropion for Attention-Deficit/Hyperactivity Disorder in Children and Adolescents. , 2017, Journal of child and adolescent psychopharmacology.

[43]  R. Glennon,et al.  Deconstructed Analogues of Bupropion Reveal Structural Requirements for Transporter Inhibition versus Substrate-Induced Neurotransmitter Release. , 2017, ACS chemical neuroscience.

[44]  Gina L Stassinos,et al.  Bupropion “Abuse” Reported to US Poison Centers , 2016, Journal of addiction medicine.

[45]  W. L. Nelson,et al.  Identification and Structural Characterization of Three New Metabolites of Bupropion in Humans. , 2016, ACS medicinal chemistry letters.

[46]  T. Lancaster,et al.  Nicotine receptor partial agonists for smoking cessation. , 2016, The Cochrane database of systematic reviews.

[47]  D. Tracy,et al.  Bupropion: a systematic review and meta-analysis of effectiveness as an antidepressant , 2016, Therapeutic advances in psychopharmacology.

[48]  K. Evoy,et al.  Combination bupropion SR and varenicline for smoking cessation: a systematic review , 2016, The American journal of drug and alcohol abuse.

[49]  I. Locatelli,et al.  Comparative efficacy and acceptability of atomoxetine, lisdexamfetamine, bupropion and methylphenidate in treatment of attention deficit hyperactivity disorder in children and adolescents: a meta-analysis with focus on bupropion. , 2015, Journal of affective disorders.

[50]  P. Shahabi,et al.  Effects of Acute Intracerebroventricular Microinfusions of Bupropion on Background Spike Activity of Locus Coeruleus Neurons in Rats , 2014, Neurophysiology.

[51]  P. Asherson,et al.  Efficacy of atomoxetine in adults with attention deficit hyperactivity disorder: An integrated analysis of the complete database of multicenter placebo-controlled trials , 2014, Journal of psychopharmacology.

[52]  J. Calabrese,et al.  The International Society for Bipolar Disorders (ISBD) task force report on antidepressant use in bipolar disorders. , 2013, The American journal of psychiatry.

[53]  Y. Koshino,et al.  The efficacy and safety of bupropion sustained-release formulation for the treatment of major depressive disorder: a multi-center, randomized, double-blind, placebo-controlled study in Asian patients , 2013, Neuropsychiatric disease and treatment.

[54]  L. Rohde,et al.  Psychopharmacology and psychotherapy for the treatment of adults with ADHD—a systematic review of available meta-analyses , 2013, CNS Spectrums.

[55]  R. Perera,et al.  Pharmacological interventions for smoking cessation: an overview and network meta-analysis. , 2013, The Cochrane database of systematic reviews.

[56]  J. Brockmöller,et al.  Genetic variability of drug-metabolizing enzymes: the dual impact on psychiatric therapy and regulation of brain function , 2013, Molecular Psychiatry.

[57]  G. Hankins,et al.  Simultaneous quantitative determination of bupropion and its three major metabolites in human umbilical cord plasma and placental tissue using high-performance liquid chromatography-tandem mass spectrometry. , 2012, Journal of pharmaceutical and biomedical analysis.

[58]  Y. de Koninck,et al.  QRS widening and QT prolongation under bupropion: a unique cardiac electrophysiological profile , 2012, Fundamental & clinical pharmacology.

[59]  C. Andrade Breast cancer and antidepressant use. , 2012, The Journal of clinical psychiatry.

[60]  A. Quante,et al.  Tranylcypromine and bupropion combination therapy in treatment-resistant major depression: a report of 2 cases. , 2012, Journal of clinical psychopharmacology.

[61]  M. Srisurapanont,et al.  Bupropion for adults with attention‐deficit hyperactivity disorder: Meta‐analysis of randomized, placebo‐controlled trials , 2011, Psychiatry and clinical neurosciences.

[62]  A. Pizon,et al.  Bupropion Induced Serotonin Syndrome: A Case Report , 2010, Journal of Medical Toxicology.

[63]  J. Wickens,et al.  Neurobiology of ADHD , 2009, Neuropharmacology.

[64]  S. Wonnacott,et al.  Comparison of the effects of bupropion and nicotine on locomotor activation and dopamine release in vivo. , 2007, Biochemical pharmacology.

[65]  J. Hughes Depression during tobacco abstinence. , 2007, Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco.

[66]  R. Kast,et al.  Bupropion: pharmacology and therapeutic applications , 2006, Expert review of neurotherapeutics.

[67]  J. Jefferson,et al.  Bupropion for major depressive disorder: Pharmacokinetic and formulation considerations. , 2005, Clinical therapeutics.

[68]  M. Shoaib,et al.  How does bupropion work as a smoking cessation aid? , 2005, Addiction biology.

[69]  Brian T. O’Neill,et al.  Varenicline: An α4β2 Nicotinic Receptor Partial Agonist for Smoking Cessation , 2005 .

[70]  R. Munhoz Serotonin syndrome induced by a combination of bupropion and SSRIs. , 2004, Clinical neuropharmacology.

[71]  G. Shepherd,et al.  Intentional bupropion overdoses. , 2004, The Journal of emergency medicine.

[72]  M. Bergström,et al.  In vivo activity of bupropion at the human dopamine transporter as measured by positron emission tomography , 2003, Biological Psychiatry.

[73]  J. Sasse,et al.  Bupropion and 4-OH-bupropion pharmacokinetics in relation to genetic polymorphisms in CYP2B6. , 2003, Pharmacogenetics.

[74]  L. Ferry,et al.  EFFICACY AND SAFETY OF BUPROPION SR FOR SMOKING CESSATION: DATA FROM CLINICAL TRIALS AND FIVE YEARS OF POSTMARKETING EXPERIENCE , 2003, International journal of clinical practice.

[75]  A. Metz,et al.  Continuation phase treatment with bupropion SR effectively decreases the risk for relapse of depression , 2002, Biological Psychiatry.

[76]  J. Avasarala,et al.  Bupropion seizure proportion among new-onset generalized seizures and drug related seizures presenting to an emergency department. , 2002, The Journal of emergency medicine.

[77]  A. Buist,et al.  Sustained-Release Bupropion for Pharmacologic Relapse Prevention after Smoking Cessation , 2001, Annals of Internal Medicine.

[78]  C. Lindley,et al.  Evaluation of the contribution of cytochrome P450 3A4 to human liver microsomal bupropion hydroxylation. , 2001, Drug metabolism and disposition: the biological fate of chemicals.

[79]  Jean Logan,et al.  Brain dopamine and obesity , 2001, The Lancet.

[80]  M. Damaj,et al.  Bupropion is a nicotinic antagonist. , 2000, The Journal of pharmacology and experimental therapeutics.

[81]  D. Greenblatt,et al.  CYP2B6 mediates the in vitro hydroxylation of bupropion: potential drug interactions with other antidepressants. , 2000, Drug metabolism and disposition: the biological fate of chemicals.

[82]  C. Lindley,et al.  Validation of bupropion hydroxylation as a selective marker of human cytochrome P450 2B6 catalytic activity. , 2000, Drug metabolism and disposition: the biological fate of chemicals.

[83]  M. Gitlin,et al.  Bupropion-tranylcypromine combination for treatment-refractory depression. , 2000, Journal of Clinical Psychiatry.

[84]  G. Chiara,et al.  Effects of nicotine on the nucleus accumbens and similarity to those of addictive drugs , 1996, Nature.

[85]  P. Wender,et al.  Bupropion treatment of attention-deficit hyperactivity disorder in adults. , 1990, The American journal of psychiatry.

[86]  N. Isoherranen,et al.  In vitro to in vivo extrapolation of the complex drug‐drug interaction of bupropion and its metabolites with CYP2D6; simultaneous reversible inhibition and CYP2D6 downregulation , 2017, Biochemical pharmacology.

[87]  H. Aubin Tolerability and Safety of Sustained-Release Bupropion in the Management of Smoking Cessation , 2012, Drugs.

[88]  Sohita Dhillon,et al.  Bupropion , 2012, Drugs.

[89]  M. Beyens,et al.  Serious Adverse Reactions of Bupropion for Smoking Cessation , 2008, Drug safety.

[90]  Maurizio Fava,et al.  15 years of clinical experience with bupropion HCl: from bupropion to bupropion SR to bupropion XL. , 2005, Primary care companion to the Journal of clinical psychiatry.

[91]  Stephen M. Stahl,et al.  A Review of the Neuropharmacology of Bupropion, a Dual Norepinephrine and Dopamine Reuptake Inhibitor. , 2004, Primary care companion to the Journal of clinical psychiatry.

[92]  D. H. Schroeder,et al.  Pharmacokinetics of bupropion, a novel antidepressant agent, following oral administration to healthy subjects , 2004, European Journal of Clinical Pharmacology.

[93]  E. A. Gardner Effects of bupropion on weight in patients intolerant to previous antidepressants , 1984 .

[94]  F. Soroko,et al.  The pharmacologic basis for therapeutic interest in bupropion. , 1983, The Journal of clinical psychiatry.

[95]  D. H. Schroeder Metabolism and kinetics of bupropion. , 1983, The Journal of clinical psychiatry.